Damora Therapeutics

Ajax Therapeutics

This biopharmaceutical company develops next-generation JAK2 inhibitors to treat patients with myeloproliferative neoplasms, a group of rare chronic blood cancers.

Imago BioSciences

This biopharmaceutical company develops small molecule inhibitors to treat patients with myeloproliferative neoplasms and other bone marrow diseases.

Atavistik Bio

This biotechnology company develops oral allosteric small molecule therapeutics for patients with rare hematological diseases and cancers.

Imara

This biopharmaceutical company develops oral small-molecule therapies to treat patients with rare genetic blood disorders, including sickle cell disease and beta thalassemia.

Velorum Therapeutics

This company develops heme-sequestering biologic drugs for patients with lung cancer, rare genetic porphyrias and heme-induced tissue injuries.

Carmot Therapeutics

This biotechnology company develops drug therapies to treat metabolic diseases, such as obesity and diabetes, for patients with these conditions.

Promedior

This biotechnology company develops drug therapies to treat rare fibrotic diseases for patients with conditions such as idiopathic pulmonary fibrosis and myelofibrosis.

Arda Therapeutics

This biotechnology company develops targeted cell depletion therapies to treat chronic diseases by identifying and removing specific pathogenic cells in patients.